Clinical trial
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment…
NCT00168766 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00168766 |
|---|---|
| Title | Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS |
| Official title | A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Relapsing-remitting Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | Interferon-beta-1a (Avonex) plus methylprednisolone |
| Enrollment | 345 |
| Start date | Jan 1, 2003 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 16, 2013 |
| Countries | Belgium, Denmark, Finland, Netherlands, Norway, Sweden, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: